Why I would buy Qantas and these ASX 200 shares with $5,000

Here's how I'd allocate $5,000 across quality ASX 200 names.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If I had $5,000 ready to invest right now, I would split it across a small group of ASX 200 shares that offer different growth drivers and time horizons.

For me, that mix would include the three shares in this article. Each brings something different to the table, and together they offer exposure to travel, healthcare technology, and global building materials.

Happy couple looking at a phone and waiting for their flight at an airport.

Image source: Getty Images

Qantas Airways Ltd (ASX: QAN)

Qantas has transformed over the past few years. It is no longer just a cyclical airline trying to survive the next downturn. I believe it is now a leaner, more disciplined operator with multiple earnings engines.

Jetstar continues to be a key growth driver, both domestically and internationally. The group's capacity discipline and focus on higher-yield routes have supported profitability, while a newer fleet should improve fuel efficiency and lower operating costs over time.

I also like the optionality from Project Sunrise, which has the potential to enhance productivity on long-haul routes. Combined with the strength of its loyalty business, Qantas looks more diversified than many people give it credit for.

With the airline now generating solid cash flow and returning capital to shareholders, I see Qantas shares as a compelling medium-term and long-term play.

Pro Medicus Ltd (ASX: PME)

Pro Medicus is one of the highest-quality growth stories on the ASX, in my view.

The company's Visage imaging platform continues to win large, multi-year contracts with leading hospitals and healthcare networks. What stands out to me is the sticky nature of these contracts. Once embedded, switching costs are high and revenue visibility improves dramatically.

Pro Medicus operates in a global medical imaging market that is still digitising and upgrading. Its technology is known for speed and scalability, which has helped it win business against much larger competitors.

Yes, the valuation is rarely cheap. But I believe this is one of those businesses where quality, execution, and long-term market opportunity justify paying a premium.

If I am investing with a 5 to 10 year horizon, I want exposure to ASX 200 shares like this.

James Hardie Industries plc (ASX: JHX)

James Hardie gives me exposure to the US housing and renovation cycle, but in a way that feels structurally advantaged.

The company is a leader in fibre cement building products, particularly in North America. Over time, it has steadily gained share as homeowners and builders shift away from traditional materials.

While housing activity can be cyclical, I believe James Hardie benefits from long-term trends such as repair and remodel demand, population growth, and the push for more durable, lower-maintenance materials.

Importantly, the business has demonstrated pricing power and a strong focus on margins. For me, that combination of market leadership and structural growth makes it more than just a housing bet.

Foolish takeaway

If I were deploying $5,000 today, I would be comfortable spreading it across Qantas, Pro Medicus, and James Hardie.

Qantas offers a revitalised airline with multiple earnings streams. Pro Medicus provides high-margin, global healthcare technology growth. James Hardie delivers exposure to US housing with structural advantages.

Together, I believe they offer a balanced blend of quality and growth that I would be happy to hold for years.

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Investing Strategies

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.
Dividend Investing

2 ASX dividend shares I'd buy for passive income right now

High yields and defensive qualities make these ASX dividend shares stand out.

Read more »

Smiling woman with her head and arm on a desk holding $100 notes, symbolising dividends.
Dividend Investing

Want a pay rise? These ASX dividend stocks could deliver one

These shares keep rewarding patient investors year after year.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Dividend Investing

How to build an ASX dividend portfolio that pays you for life

Quality businesses, reliable cash flow, and growth create lasting dividends.

Read more »

Man holding Australian dollar notes, symbolising dividends.
Dividend Investing

How much could a $400,000 ASX share portfolio pay in dividends?

You don't need a million dollar portfolio to earn a good passive income.

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Dividend Investing

Chasing $500 a month in passive income? Here's how

The maths behind a $6,000 annual dividend income stream.

Read more »

$50 dollar notes jammed in the fuel filler of a car.
Dividend Investing

How many Woodside shares do I need to buy for a $1,000 monthly passive income?

Atop this year’s 37% share price gains, Woodside shares offer attractive passive income.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Dividend Investing

122,353 shares of this high-yield ASX dividend stock pays an income equal to the Age Pension

This high-yield dividend stock offers a lot of positives.

Read more »

A casually dressed woman at home on her couch looks at index fund charts on her laptop.
Blue Chip Shares

My highest-conviction ASX share for August

The business is already a global leader, yet its market may still be in the early stages.

Read more »